|
1
|
Qi WX, Zhao S, Chen J. Risk factors for developing osteonecrosis of jaw in advanced cancer patients underwent zoledronic acid treatment. Future Oncol 2019; 15:3503-3511. [PMID: 31580147 DOI: 10.2217/fon-2019-0352] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Aim: To investigate the risk factors for developing osteonecrosis of jaw (ONJ) in advanced cancer patients with bone metastases underwent zoledronic acid (ZA) treatment. Materials & methods: Univariate and multivariate logistic regression analyses were performed to investigate factors associated with developing ONJ in advanced cancer patients. Results: A total of 2214 advanced cancer patients were included. Univariate and multivariate logistic regression analyses for risk factors associated with ONJ were older age (≥66 years, hazards ratio [HR]: 3.21; p = 0.007), anemia (HR: 3.29; p = 0.006) and duration of ZA exposure (between 1 and 2 years, HR: 3.91, p = 0.01; ≥2 years, HR: 8.07, p < 0.001), respectively. Conclusion: Patients with older age, anemia and/or more than 1 year of ZA treatment are at high risk of developing ONJ.
Collapse
Affiliation(s)
- Wei-Xiang Qi
- Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, PR China
| | - Shengguang Zhao
- Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, PR China
| | - Jiayi Chen
- Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, PR China
| |
Collapse
|
|
2
|
Fu S, Ou YN, Sheng ZF. Long-term control of Paget's disease of bone with low-dose, once-weekly, oral bisphosphonate preparations, in a "real world" setting. Endocrine 2019; 65:223-224. [PMID: 31154606 DOI: 10.1007/s12020-019-01966-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/13/2019] [Accepted: 05/22/2019] [Indexed: 10/26/2022]
Affiliation(s)
- Sang Fu
- Department of Metabolism and Endocrinology; National Clinical Research Center for Metabolic Diseases, Institution of Metabolism and Endocrinology of Central South University, Second Xiangya Hospital, Central South University, 410011, Changsha, Hunan, People's Republic of China
| | - Yang-Na Ou
- Hospital Infection Control Center, Second Xiangya Hospital, Central South University, 410011, Changsha, Hunan, People's Republic of China
| | - Zhi-Feng Sheng
- Department of Metabolism and Endocrinology; National Clinical Research Center for Metabolic Diseases, Institution of Metabolism and Endocrinology of Central South University, Second Xiangya Hospital, Central South University, 410011, Changsha, Hunan, People's Republic of China.
| |
Collapse
|
|
3
|
Liel Y, Abu Tailakh M. Long-term control of Paget's disease of bone with low-dose, once-weekly, oral bisphosphonate preparations, in a "real world" setting. Endocrine 2019; 65:225. [PMID: 31165411 DOI: 10.1007/s12020-019-01967-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/29/2019] [Accepted: 05/22/2019] [Indexed: 11/29/2022]
Affiliation(s)
- Yair Liel
- Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
| | - Muhammad Abu Tailakh
- Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
| |
Collapse
|